Algeta Asa
Pharmaceuticals, 210 Broadway, Cambridge, Massachusetts, 02139, United States, 51-200 Employees
Who is ALGETA ASA
March 6th The Bayer Group completed the voluntary takeover offer for Norwegian pharmaceutical company Algeta ASA, Oslo. As a result, Bayer now holds 98.2 % of the shares and voting rights...
Read More
-
Headquarters: 210 Broadway, Cambridge, Massachusetts, 02139, United States
-
Date Founded: 1997
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 5122
|
NAICS Code: 999990 |
Show More
Does something look wrong? Fix it. | View contact records from ALGETA ASA
Algeta ASA Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Algeta ASA
Answer: Algeta ASA's headquarters are located at 210 Broadway, Cambridge, Massachusetts, 02139, United States
Answer: Algeta ASA's official website is https://algeta.com
Answer: Algeta ASA's revenue is $10 Million to $25 Million
Answer: Algeta ASA's SIC: 5122
Answer: Algeta ASA's NAICS: 999990
Answer: Algeta ASA has 51-200 employees
Answer: Algeta ASA is in Pharmaceuticals
Answer: Algeta ASA contact info: Phone number: Website: https://algeta.com
Answer: March 6th The Bayer Group completed the voluntary takeover offer for Norwegian pharmaceutical company Algeta ASA, Oslo. As a result, Bayer now holds 98.2 % of the shares and voting rights in Algeta. Bayer intends to initiate a compulsory acquisition process in order to acquire the remaining shares of minority shareholders in Algeta in the coming days. Bayer intends to file for delisting of the Algeta shares from the Oslo Stock Exchange (OSE). Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. Algeta's lead product Xofigo injection (radium Ra 223 dichloride, radium-223; previously called Alpharadin) is an alpha particle-emitting pharmaceutical with an anti-tumor effect on bone metastases. In September 2009, Algeta signed an agreement with Bayer for the development and commercialization of Xofigo. Under the terms of this agreement, Bayer will develop, apply for health authority approvals worldwide and commercialize Xofigo globally. Algeta is eligible for royalties and milestones based on Bayers sales of Xofigo outside the US, and Algeta US is co-promoting Xofigo with Bayer in the US. Algeta is also evaluating the potential of Targeted Thorium Conjugates (TTCs), which are based on conjugating the alpha-emitter thorium-227 to targeting molecules, as a basis of a potential future pipeline of tumor-targeting alpha-pharmaceutical candidates. In December 2013, the Board of Directors of Algeta ASA announced that it had unanimously recommended the voluntary cash offer (the Offer) of NOK 362 per share from Bayer to acquire the entire issued share capital of Algeta.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month